Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma : A Systematic Review and Meta-Analysis
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya))
González-Cao, María (Hospital Dexeus)
Domine, Manuel (Hospital Universitario Fundación Jiménez Díaz)
de Castro, Javier (Hospital Universitario La Paz (Madrid))
Cobo, Manuel (Instituto de Investigación Biomédica de Málaga)
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia)
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau)
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Mosquera, Joaquín (Complejo Hospitalario Universitario de A Coruña)
Crama, Leonardo (Medical Department Roche)
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)

Fecha:	2022
Resumen:	Introduction: The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. Methods: Two independent reviewers extracted relevant data according to PRISMA guidelines and assessed the risk of bias using the Cochrane Collaboration's risk-of-bias tool. Meta-analysis was conducted using random-effects models to calculate an average effect size for overall survival (OS), progression-free survival (PFS), and safety outcomes in the overall populations and clinically relevant subgroups. Results: A literature search of PubMed and Embase was performed. Six randomized controlled clinical trials (IMpower133, CHECKMATE-451, CASPIAN, KEYNOTE-604, and phase II and III ipilimumab plus CT trials) with a total of 3757 patients were included. Compared with CT alone, ICIs plus CT showed a favourable effect on OS (hazard ratio [HR] 0. 85; 95% confidence intervals [CI] 0. 79-0. 96) and PFS (HR 0. 78; 95% CI 0. 72-0. 83) but a non-significant increase in the risk of experiencing any adverse event (relative risk, 1. 05; 95% CI 0. 99-1. 11). The estimated HR for OS favoured ICI combinations in all planned subgroups according to age (< 65 years/≥ 65 years), sex (men/women), and ECOG performance status (0/1). Analysis by specific ICI revealed significant improvements in OS only for atezolizumab + CT (HR 1. 36; 95% CI 1. 09-1. 69) and durvalumab + CT (HR 1. 35; 95% CI 1. 12-1. 62) compared with CT alone. Conclusion: Combining anti-programmed cell death ligand 1 antibodies with platinum/etoposide is a superior therapeutic approach compared to CT alone for the first-line treatment of patients with ES-SCLC. Graphic abstract: [Figure not available: see fulltext. ].
Nota:	Altres ajuts: Roche.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Anti-PD-1/PD-L1 antibodies ; Chemotherapy ; Immunotherapy ; Metaanalysis ; Small cell lung carcinoma
Publicado en:	Oncology and Therapy, Vol. 10 Núm. 1 (june 2022) , p. 167-184, ISSN 2366-1089

DOI: 10.1007/s40487-021-00182-0
PMID: 35032007

18 p, 1.7 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados